Beau Ances (Washington University in St Louis, MO, USA) discusses recent research on amyloid biomarkers in people with genetic forms of Alzheimer’s disease; his Article is published in the January issue of The Lancet Neurology. Read the full article: Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer's disease ... Show More
Jun 17
Hal Dietz discusses the role of genetics in spinal CSF leaks
In this episode of In Conversation With, Morgane Boillot, Senior Editor at The Lancet Neurology, speaks with connective tissue disorders — including Marfan syndrome — and human genetics expert Hal Dietz from Johns Hopkins Medicine (Baltimore, USA) about the genetics of spontaneou ... Show More
16m 23s
Jun 16
Tony Schapira on GBA1 Parkinson's disease
In this episode of In Conversation With, Elena Becker-Barroso, Editor-in-Chief of The Lancet Neurology, speaks with movement disorders specialist Tony Schapira from UCL’s Queen Square Institute of Neurology about GBA1-associated Parkinson’s disease. Together, they explore the gen ... Show More
26m 5s
Aug 2023
Monoclonal Antibodies Targeting Amyloid for Alzheimer Disease
<p>In this interview, dementia expert Gil D. Rabinovici, MD, discusses monoclonal antibodies that target beta-amyloid–-including a recent phase 3 trial of donanemab published in JAMA-–and reviews considerations for their use in patients with Alzheimer disease.<br /> <br /> <stron ... Show More
28m 48s
Oct 2018
#043 Dr. Dale Bredesen on Preventing and Reversing Alzheimer's Disease
<p><strong>Dale E. Bredesen</strong></p> <p>Dale E. Bredesen, M.D., is a professor of neurology at the Easton Laboratories for Neurodegenerative Disease Research at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA).</p> <p>Dr. Bredesen's labo ... Show More
1h 14m